DSM265 Prophylaxis of Plasmodium Falciparum Malaria

Healthy Clinical Trial

Official title:

Proof-of-concept, Single Center Study in Healthy Adult Volunteers to Investigate Safety, Tolerability, Pharmacokinetics and Prophylactic Activity of Single Dose DSM265 in a Controlled Human Malarial Infection Challenge Either by Direct Venous Inoculation of Plasmodium Falciparum Sporozoites or Mosquito-borne Plasmodium Falciparum

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02562872
• Other study ID #: MMV_DSM265_14_03
• Secondary ID: CDMRP-PR130402
• Status: Completed
• Phase: Phase 1
• Start date: March 2016
• Est. completion date: May 2017

Study information

• Verified date: January 2022
• Source: Medicines for Malaria Venture
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a single centre, randomised, placebo-controlled, double-blind study with DSM265 including up to two cohorts of healthy male and female volunteers aged 18 to 45 years.

The study will be conducted into two sequential parts (Cohort 1 and Cohorts 2a and 2b).

Description:

Cohort 1:

• Controlled human malaria infection on Day 0 (Direct Venous Inoculation of 3200 cryopreserved Plasmodium falciparum sporozoites)

• Drug administration on Day -3

• 8 subjects: 6 DSM265 400 mg: 2 matching placebo Clinical safety review of Cohort 1 in order to proceed to Cohorts 2a and 2b

Cohort 2a:

• Controlled human malaria infection on Day 0 (Direct Venous Inoculation of 3200 cryopreserved Plasmodium falciparum sporozoites)

• Drug administration on Day -X (to be defined following safety and pharmacokinetic data)

• 8 subjects: 6 DSM265 400 mg: 2 matching placebo

Cohort 2b:

• Controlled human malaria infection on Day 0 (infected mosquito bite)

• Drug administration on Day -X (to be defined following safety and pharmacokinetic data)

• 8 subjects: 6 DSM265 400 mg: 2 matching placebo

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

• Good health based on medical history and physical examination

• body mass index >18 and <30kg/m2

• Laboratory results without clinically significant findings within 60 days

• Males must use medically acceptable form of contraception from the dose of DSM265/Placebo for 120 days

• Women must be of non-child bearing potential or willing and able to practice one of the required continuous acceptable methods of contraception and have negative pregnancy tests

• Able & willing to comply with all study requirements throughout the study

• Agree to undergo all study procedures, attend all study visits and stay overnight for observation if required, to last follow-up visit

• Willing to undergo a controlled human malaria infection by mosquito bites / inoculation

• Able and willing to answer all questions on informed consent correctly, and to sign the informed consent form

• Reachable constantly by mobile phone or email throughout the study period

• Refrain from blood donation throughout the study

• Willing to take atovaquone-proguanil, Chloroquine or other registered antimalarial

Exclusion Criteria:

• Any history of malaria; any severe reactions to mosquito or insect bites; any history of anaphylaxis

• Plans to travel to malaria endemic region during the study period

• Previous participation in any malaria vaccine study or controlled human malaria infection study

• Participation in any other clinical study within 30 days of enrollment or plan to participate in another investigational vaccine/drug research during the study

• Breastfeeding or planning to become pregnant during the time of the study

• Positive Human Immunodeficiency Virus, Hepatitis B or C tests

• Any confirmed/suspected immunosuppressive or immunodeficient state

• History of serious psychiatric condition that may affect participation in the study, or history of convulsions, seizures, or of severe head trauma

• Symptoms, physical signs or laboratory values suggestive of systemic disorders

• History of cancer (except basal cell carcinoma of the skin)

• History of arrhythmias or documented prolonged QTcF-interval (>450 msec) or 12-lead ECG demonstrating specific abnormalities

• Moderate risk or higher for cardiovascular event within 5 years (>10%)

• Positive family history in 1st or 2nd degree relative <50 years for cardiac disease, or history of, or known active cardiac disease

• history of: psoriasis or porphyria which may be exacerbated by chloroquine; splenectomy, or sickle cell anaemia or other red blood cell disorders; allergy or contra-indication to chloroquine or atovaquone-proguanil

• Treatment with an investigational drug within 28 days or 5 half-lives of study medication; use of any drugs or dietary supplements within 7 days or 5 half-lives prior to study medication. Herbal supplements must be discontinued at least 28 days prior to study medication. As an exception, acetaminophen or ibuprofen may be used as approved by the investigator

• Use of any prohibited medication

• Grapefruit or product containing grapefruit from28 days before study medication or throughout the study

• History of drug or alcohol abuse within 12 months prior to dosing, or laboratory evidence of abuse

• Current smoking of more than 10 cigarettes or equivalent per day

• Plan for major surgery between enrolment and study completion

Related Conditions & MeSH terms

• Healthy
• Malaria

Intervention

Drug:
• DSM265
DSM265 400 mg single oral dose
• Placebo
Placebo to match DSM265, single oral dose

Biological:
• Sporozoites
Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites
• Infective mosquito bite
Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum

Locations

Country	Name	City	State
United States	Fred Hutchinson Cancer Research Center - Prevention Center	Seattle	Washington

Sponsors (4)

Lead Sponsor	Collaborator
Medicines for Malaria Venture	Center for Infectious Disease Research, Fred Hutchinson Cancer Research Center, United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with positive parasitemia	positive parasitemia detected by qRT-PCR	28 days
Primary	Time interval between challenge and the first positive parasitemia	Time from infection to peripheral parasitemia (qRT-PCR) in DSM265 / placebo treated subjects in each cohort given as a geometric mean [days]	28 days